Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00984620 · ClinicalTrials.gov registry record · Phase 2
Short Term Treatment With BI 201335, Peginterferon-alpha 2a and Ribavirin in Hepatitis c Virus Genotype-1 Treatment-naïve Patients (SILEN-C3)
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
NCT00984620 is a Phase 2 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 160 participants.
The verdict
NCT00984620, a Phase 2 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
Study Summary
To compare the antiviral efficacy and safety of a 12-week with a 24-week treatment of BI 201335 at a dose of 120 mg once daily, with a 24-week background of pegylated interferon-alpha 2a (PegIFN) plus ribavirin (RBV), in treatment-naïve patients infected with hepatitis C virus (HCV) genotype 1
Interventions
- DRUG Ribavirin (RBV)
- DRUG BI 201335
- DRUG Pegylated Interferon-alpha (IFN)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2009-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00984620
The ClinicalTrials.gov registry entry for NCT00984620 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ribavirin (RBV) is the first listed.
NCT00984620 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00984620 about?
NCT00984620 is a clinical study titled "Short Term Treatment With BI 201335, Peginterferon-alpha 2a and Ribavirin in Hepatitis c Virus Genotype-1 Treatment-naïve Patients (SILEN-C3)". To compare the antiviral efficacy and safety of a 12-week with a 24-week treatment of BI 201335 at a dose of 120 mg once daily, with a 24-week background of pegylated interferon-alpha 2a (PegIFN) plus ribavirin (RBV), in treatment-naïve patients infected with hepatitis C virus (HCV) genotype 1
What is the current status of trial NCT00984620?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2009-09.
What interventions are being tested in trial NCT00984620?
The interventions under investigation include: Ribavirin (RBV) (DRUG), BI 201335 (DRUG), Pegylated Interferon-alpha (IFN) (DRUG).
Who is sponsoring clinical trial NCT00984620?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.